Nanjing, China

Sulin Ren

USPTO Granted Patents = 2 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
2 patents (USPTO):

Title: The Innovative Contributions of Sulin Ren in Hepatitis B Treatment

Introduction

Sulin Ren is an accomplished inventor based in Nanjing, China, recognized for her significant contributions to the field of pharmaceutical innovations. Her work focuses particularly on developing treatments for hepatitis B, a viral infection affecting millions worldwide.

Latest Patents

Sulin Ren holds a patent for a groundbreaking pharmaceutical preparation aimed at treating hepatitis B. The invention, titled "Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof," involves a carefully formulated solution that includes hepatitis B surface antigen, hepatitis B core antigen, and oligodeoxynucleotide solution. This preparation stands out due to its simple composition and the absence of saccharides, which enhances antigen stability and minimizes adverse reactions related to aluminum adjuvants. The long-term stability experiments demonstrate effective preservation, making it a promising candidate for hepatitis B treatment.

Career Highlights

Sulin is currently employed at Grand Theravac Life Sciences (Nanjing) Co., Ltd., where she applies her expertise to advance medical research and pharmaceutical developments. Her work within the company is pivotal in outlining innovative strategies to combat viral infections, particularly hepatitis B.

Collaborations

In her professional journey, Sulin has collaborated closely with notable coworkers such as Jianqiang Li and Jun Ge. These partnerships enhance her research capabilities, fostering a collaborative environment that drives the advancement of innovative solutions in healthcare.

Conclusion

Sulin Ren exemplifies the spirit of innovation within the pharmaceutical industry through her dedication to developing effective treatments for hepatitis B. Her patent signifies a notable step forward in medical research, promising improved health outcomes for those affected by the disease. As she continues her work at Grand Theravac Life Sciences, her contributions will undoubtedly shape the future of hepatitis B treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…